StocksLockheed Martin CorporationLMT

LMT

Lockheed Martin Corporation

386.29 -3.50 (-0.90%)
Precios retrasados ofrecidos por el índice NASDAQ, en USD Mercado cerrado
Invertir
V
386.22
C
387.97
Publicación incluida
Max Molter
FUNDAMENTAL ANALYSIS - LOCKHEED MARTIN ★ WHAT IS LOCKHEED MARTIN ? $LMT (Lockheed Martin Corporation) is an American military company with a market capitalization of more than 110 Billion USD. It mainly produces jets but also other weapons for the USA and their allies. ★ FUNDAMENTALS P/B-Ratio (average*):... Mostrar más Traducir
Canal de mercado
Destacado
Steeve Esquis
Editado
.⭐ 𝐒𝐈𝐌𝐏𝐋𝐘 𝐒𝐀𝐅𝐄 𝐃𝐈𝐕𝐈𝐃𝐄𝐍𝐃𝐒 𝐈𝐍𝐂𝐎𝐌𝐄 ⭐ .🎯 Dividends increase 🎯 .𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 >𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗥𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝘀 Hi investors, We will start this new week with why we are setting up a long-term investment pocket: dividends, and more particularly the increase in dividend... Mostrar más Traducir
John Delves
✈ 𝙃𝙤𝙡𝙙𝙞𝙣𝙜 𝘿𝙞𝙫𝙞𝙙𝙚𝙣𝙙𝙨 𝙛𝙤𝙧 𝙋𝙖𝙨𝙨𝙞𝙫𝙚 𝙄𝙣𝙘𝙤𝙢𝙚 ✈ 🔊 Weekly Update With October starting, we prepare to enter another earnings season. We will expect some volatility this month, but it is a good opportunity for our value stocks to reverse direction if earnings are better than... Mostrar más Traducir
Pawel Lech Cylkowski
Editado
𝗠𝗼𝗻𝘁𝗵𝗹𝘆 𝗩𝗜𝗗𝗘𝗢 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝘂𝗽𝗱𝗮𝘁𝗲 - 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟮 Dear Copiers and Followers, It's been another extremely tough month for the risky assets markets. No single assset class has been spared, be it stocks, bonds, FX or $GOLD. The markets are facing extreme conditions... Mostrar más Traducir
Martins Krusts
Small update on portfolio: today i opened back $AIR.PA (AIRBUS SE) shares. So i made a picture of history at which prices i have opened and closed Airbus stocks - for both, myself and copiers. Basically, Airbus have been relatively calm. I was tended to close some shares above symbolic 100 eiro a share... Mostrar más Traducir
4headtrade
Editado
🔔Mid Day Trading Update🔔 📅Wednesday 28/9/2022📅 🟢Bullish Activity🟢 $BIIB (Biogen Inc) Leading the gainers list this morning after the company’s experimental Alzheimer’s drug lecanemab, which is being developed with Japanese partner Eisai, slowed cognitive and functional decline in patients who... Mostrar más Traducir
Me gusta ComentarCompartir
null
.